To investigate this risk, Pieber et al conducted a study comparing clinical,physiological, and counterregulatory hormone responses to double and triple doses oficodec with IGlar U100 in a 2-period crossover study in participants with T2D who werealready on insulin ± oral glucose-lowering medication (124). The gene discussed is INS; the disease is type 2 diabetes mellitus.